ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (01541)
| Auditor | From | To | Release Date / Document Links | Reason for Change |
|---|---|---|---|---|
| Deloitte (Hong Kong) | 24-Aug-23 | |||
| Zhonghui Anda CPA | ||||
| Deloitte | 28-Oct-26 | Deloitte Touche Tohmatsu and the Company were unable to reach an agreement on the audit fee for the audit of the consolidated financial statements for the year ending December 31, 2026. The disagreement arose from an increase in audit scope and workload (and a proposed incremental fee by Deloitte) resulting from the capital increase of a subsidiary and related transactions, including valuation considerations and the business development of that subsidiary. |